BTIG Research Raises Crispr Therapeutics (CRSP) Price Target to $33.00
Crispr Therapeutics (NASDAQ:CRSP) had its price objective lifted by equities researchers at BTIG Research from $30.00 to $33.00 in a research report issued to clients and investors on Monday, The Fly reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s target price suggests a potential downside of 14.68% from the stock’s previous close.
Other equities research analysts have also issued research reports about the stock. BidaskClub lowered shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, March 22nd. Evercore ISI began coverage on shares of Crispr Therapeutics in a report on Thursday, April 11th. They issued an “outperform” rating on the stock. Zacks Investment Research lowered shares of Crispr Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, March 13th. Goldman Sachs Group lowered shares of Crispr Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $78.00 to $40.00 in a report on Monday, January 28th. Finally, William Blair began coverage on shares of Crispr Therapeutics in a research report on Wednesday, March 13th. They issued a “market perform” rating for the company. Three research analysts have rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $44.32.
Shares of NASDAQ CRSP opened at $38.68 on Monday. Crispr Therapeutics has a 1-year low of $22.22 and a 1-year high of $73.90. The stock has a market cap of $1.96 billion, a PE ratio of -11.24 and a beta of 3.11.
In other Crispr Therapeutics news, President Rodger Novak sold 8,693 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $40.01, for a total value of $347,806.93. Following the completion of the sale, the president now directly owns 1,024,534 shares of the company’s stock, valued at approximately $40,991,605.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 108,693 shares of company stock valued at $4,381,895 over the last ninety days. 37.70% of the stock is currently owned by insiders.
A number of hedge funds have recently modified their holdings of the business. Versant Venture Management LLC grew its position in shares of Crispr Therapeutics by 17.7% during the 1st quarter. Versant Venture Management LLC now owns 4,248,888 shares of the company’s stock valued at $151,770,000 after acquiring an additional 640,014 shares during the period. Federated Investors Inc. PA grew its position in shares of Crispr Therapeutics by 21.0% during the 3rd quarter. Federated Investors Inc. PA now owns 764,263 shares of the company’s stock valued at $33,895,000 after acquiring an additional 132,863 shares during the period. BlackRock Inc. grew its position in shares of Crispr Therapeutics by 19.6% during the 3rd quarter. BlackRock Inc. now owns 709,643 shares of the company’s stock valued at $31,471,000 after acquiring an additional 116,116 shares during the period. Ontario Teachers Pension Plan Board bought a new position in shares of Crispr Therapeutics during the 4th quarter valued at approximately $16,598,000. Finally, Two Sigma Investments LP grew its position in shares of Crispr Therapeutics by 25.2% during the 4th quarter. Two Sigma Investments LP now owns 509,572 shares of the company’s stock valued at $14,558,000 after acquiring an additional 102,478 shares during the period. 43.46% of the stock is owned by institutional investors and hedge funds.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: Relative Strength Index
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.